Drug Profile


Alternative Names: Mometasone furoate/indacaterol; Mometasone/indacaterol; QMF-149

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Glucocorticoids; Indans; Pregnadienediols; Quinolones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Sep 2016 Novartis Pharmaceuticals plans a phase III trial for Asthma (In adolescents, In adults, Adjunctive treatment) in European Union (Inhalation) (NCT02892344)
  • 01 Dec 2015 Phase-III clinical trials in Asthma (In adolescents, In adults) in Czech Republic, Japan, Estonia, Hungary, Latvia, Slovakia, United Kingdom, Germany, Lithuania, Bulgaria, Croatia (Inhalation) (NCT02554786)
  • 24 Sep 2015 Novartis plans a phase III trial for Asthma in European Union (Inhalation) (NCT02554786)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top